Silence Therapeutics PLC Results of Placing (9592D)
October 12 2018 - 11:12AM
UK Regulatory
TIDMSLN
RNS Number : 9592D
Silence Therapeutics PLC
12 October 2018
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION
CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION
OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN,
INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN
WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL.
For immediate release
Patisserie Holdings PLC
12 October 2018
Results of Placing to raise approximately GBP15.7m
Further to the earlier announcement in relation to the proposed
placing of ordinary shares, the Company announces that 31,451,100
ordinary shares (the "Placing Shares") have been placed with
institutional investors and were placed at a price of 50p per share
via an accelerated bookbuild (the "Placing"). Canaccord Genuity
("Canaccord Genuity") acted as nominated adviser, sole bookrunner
and broker in connection with the Placing. The Placing raised
approximately GBP15.7 million before expenses.
Application will be made for the admission of 31,451,100
ordinary shares to trading on AIM. It is expected that admission of
(a) the Firm Placing Shares comprising 10,000,000 ordinary shares
will become effective at 8.00 a.m. on 18 October 2018 and that
dealings in the Firm Placing Shares will commence at that time and
(b) the Conditional Placing Shares comprising 21,451,100 ordinary
shares will become effective at 8.00 a.m. on the Business Day
following the General Meeting of the Company (expected to on or
around 1 November 2018) and that dealings in the Firm Placing
Shares will commence at that time and the Placing Shares shall rank
pari passu with the existing issued ordinary shares of the
Company.
Following completion of the Placing the Company will have
135,322,452 Ordinary Shares in issue.
Enquiries
Patisserie Holdings PLC +44 (0)121 777 7000
Luke Johnson, Executive Chairman
Paul May, Chief Executive Officer
Nomad and Broker
Canaccord Genuity Limited +44 (0)20 7523 8000
Chris Connors
Henry Fitzgerald-O'Connor
Financial Public Relations
Maitland +44 (0) 20 7379 5151
Sam Cartwright
Jonathan Cook
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROIEAKEAFFFPFFF
(END) Dow Jones Newswires
October 12, 2018 12:12 ET (16:12 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024